224 related articles for article (PubMed ID: 37400572)
1. Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
Xiong B; Fu B; Wu Y; Gao F; Hou C
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11607-11617. PubMed ID: 37400572
[TBL] [Abstract][Full Text] [Related]
2. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
[TBL] [Abstract][Full Text] [Related]
3. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
Liu M; Jin Q; Wang H; Li Y
Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
[TBL] [Abstract][Full Text] [Related]
4. Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study.
Xiao LS; Li RN; Cui H; Hong C; Huang CY; Li QM; Hu CY; Dong ZY; Zhu HB; Liu L
BMC Cancer; 2022 Jul; 22(1):737. PubMed ID: 35794525
[TBL] [Abstract][Full Text] [Related]
5. Body Composition Changes in Hepatocellular Carcinoma: Prediction of Survival to Transcatheter Arterial Chemoembolization in Combination With Clinical Prognostic Factors.
Zheng X; Cao F; Qian L; Dong J
Cancer Control; 2021; 28():10732748211038445. PubMed ID: 34569304
[TBL] [Abstract][Full Text] [Related]
6. Effect of Body Composition on Outcomes in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy: A Retrospective Study.
Li LQ; Zhao WD; Su TS; Wang YD; Meng WW; Liang SX
Nutr Cancer; 2022; 74(9):3302-3311. PubMed ID: 35543186
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.
Fujiwara N; Nakagawa H; Kudo Y; Tateishi R; Taguri M; Watadani T; Nakagomi R; Kondo M; Nakatsuka T; Minami T; Sato M; Uchino K; Enooku K; Kondo Y; Asaoka Y; Tanaka Y; Ohtomo K; Shiina S; Koike K
J Hepatol; 2015 Jul; 63(1):131-40. PubMed ID: 25724366
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting overall survival and disease-free survival after surgery for hepatocellular carcinoma: a nomogram-based prognostic model-a Western European multicenter study.
Masuda Y; Yeo MHX; Burdio F; Sanchez-Velazquez P; Perez-Xaus M; Pelegrina A; Koh YX; Di Martino M; Goh BKP; Tan EK; Teo JY; Romano F; Famularo S; Ferrari C; Griseri G; Piardi T; Sommacale D; Gianotti L; Molfino S; Baiocchi G; Ielpo B
Updates Surg; 2024 Jan; 76(1):57-69. PubMed ID: 37839048
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy.
Kuang T; Zhang L; Qiu Z; Zhang Y; Wang W
Front Immunol; 2023; 14():1261202. PubMed ID: 38077332
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
Cancer Manag Res; 2018; 10():2231-2239. PubMed ID: 30100754
[TBL] [Abstract][Full Text] [Related]
12. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.
Fu YP; Yi Y; Huang JL; Jing CY; Sun J; Ni XC; Lu ZF; Cao Y; Zhou J; Fan J; Qiu SJ
Oncologist; 2017 May; 22(5):561-569. PubMed ID: 28438885
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
Zhang R; Zhao H; Wang P; Guo Z; Liu C; Qu Z
BMC Cancer; 2023 Dec; 23(1):1181. PubMed ID: 38041022
[TBL] [Abstract][Full Text] [Related]
15. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
16. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis.
Ebadi M; Tandon P; Moctezuma-Velazquez C; Ghosh S; Baracos VE; Mazurak VC; Montano-Loza AJ
J Hepatol; 2018 Sep; 69(3):608-616. PubMed ID: 29709682
[TBL] [Abstract][Full Text] [Related]
17. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Han CL; Meng GX; Xue JS; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Int Immunopharmacol; 2023 Jan; 114():109519. PubMed ID: 36459922
[TBL] [Abstract][Full Text] [Related]
18. The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors.
Liu C; Zhao H; Wang P; Guo Z; Qu Z
Int Immunopharmacol; 2023 Oct; 123():110704. PubMed ID: 37506504
[TBL] [Abstract][Full Text] [Related]
19. A novel nomogram based on body composition and nutritional indicators to predict the prognosis of patients with muscle-invasive bladder cancer undergoing radical cystectomy.
Zhong X; Pan Y; Wu K; Wang L; Dou P; Tan P; Zhang P; Li X
Cancer Med; 2023 Dec; 12(24):21627-21638. PubMed ID: 37975152
[TBL] [Abstract][Full Text] [Related]
20. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]